• No products in the list

FV-PTH mpx PCR Assay

Short description

The FV-PTH mpx RealFast™ Assay is a highly efficient multiplex real-time PCR test designed for the simultaneous detection of two critical thrombophilic mutations: the FV Leiden (1691G>A) mutation in the Factor V (F5) gene and the prothrombin (PTH) 20210G>A mutation in the Factor II (F2) gene. These mutations are associated with hereditary thrombophilia, increasing the risk of thrombotic disorders. This assay accurately identifies patients with normal, heterozygous, or homozygous mutant genotypes for each mutation, enabling prompt diagnosis and risk assessment. It offers fast, reliable results, making it a valuable tool for assessing thrombophilia risk.

Product highlights

  • Thrombophilia Assessment
  • Multiplex Testing
  • Genetic Mutation Detection
  • Real-time PCR

Ask for a quote

FV-PTH mpx PCR Assay



Instructions for Use

For any missing information or if you require additional details, please do not hesitate to contact us. 

Specifications of the FV-PTH mpx PCR Assay

The FV-PTH mpx RealFast™ Assay: Detecting Thrombophilic Mutations

Cardiovascular diseases (CVD) pose a significant health risk worldwide, encompassing conditions like atherosclerosis and venous thrombosis. Genetic factors can play a pivotal role in the development of these diseases, particularly in conjunction with an unhealthy lifestyle. ViennaLab Diagnostics GmbH offers a crucial tool to identify individuals at risk. The FV-PTH mpx RealFast™ Assay is a multiplex real-time PCR test designed to detect two critical thrombophilic mutations: Factor V Leiden (FV) and Prothrombin (PTH) 20210G>A. This assay helps clinicians assess a patient’s susceptibility to thrombotic disorders and tailor their medical care accordingly.

Understanding Thrombophilia

Thrombophilia is a condition characterized by an increased tendency to develop abnormal blood clots, known as thromboses. Two common genetic mutations, Factor V Leiden and Prothrombin 20210G>A, significantly elevate the risk of thrombosis when present.

  1. Factor V Leiden (FV): This mutation results from a point mutation (1691G>A) in the human coagulation Factor V (F5) gene, leading to a single amino acid change at position 506 (R506Q). This alteration hinders the efficient inactivation of Factor V, causing increased clot formation in veins.
  2. Prothrombin (PTH) 20210G>A: Found in the Factor II (F2) gene, this mutation occurs in the 3′ untranslated region. It leads to higher mRNA synthesis, resulting in elevated prothrombin plasma levels, excessive thrombin generation, and an increased risk of fibrin clot formation.

Heterozygous carriers of FV Leiden have a 5 to 10 times higher risk of venous thrombosis, while homozygous carriers face a 50 to 100 times higher risk compared to non-carriers. Similarly, heterozygous carriers of PTH 20210G>A have a threefold increased risk, with homozygous carriers at up to 20 times higher risk. Individuals with additional risk factors, such as other thrombophilic mutations, obesity, hypertension, type 2 diabetes, smoking, or the use of oral contraceptives, are even more predisposed to venous thrombotic events.

The Principle of the Test

This assay relies on the fluorogenic 5′ nuclease assay, commonly known as the TaqMan® assay. Each reaction contains two gene-specific primer pairs, enabling the amplification of a 142 bp fragment of the F5 gene and a 110 bp fragment of the F2 gene. Four dual-labeled, allele-specific hydrolysis probes specifically bind to the target sequences of these amplified fragments. During the PCR extension phase, the 5′ – 3′ exonuclease activity of the Taq DNA polymerase cleaves the 5’-fluorescent reporter from the hybridized probe. This physical separation of the fluorophore from the quencher dye generates a real-time fluorescent signal proportional to the accumulated PCR product.

  • In normal samples, the wild type probes generate a strong fluorescence signal in the HEX or Cy5 channel and little to no signal in the FAM or ROX channel.
  • Conversely, in homozygous mutant samples, the hybridized mutant probes generate a strong fluorescence signal in the FAM or ROX channel and little to no signal in the HEX or Cy5 channel.
  • In heterozygous samples, both wild type and mutant probes bind to the amplicons, generating intermediate signals in the respective channels.


The FV-PTH mpx RealFast™ Assay by ViennaLab Diagnostics GmbH empowers healthcare professionals to swiftly and accurately detect critical thrombophilic mutations, allowing for timely intervention and tailored patient care. This assay serves as a vital tool in assessing the risk of thrombotic disorders, enabling early diagnosis, and ultimately contributing to improved patient outcomes in the realm of cardiovascular health.

Components of the FV-PTH mpx PCR Assay
  • RealFast™ 2x mpx Probe Mix: This mix contains HotStart Taq DNA polymerase and dNTPs in an optimized buffer system to enable precise amplification.
  • FV-PTH mpx Assay Mix: This mix includes gene-specific primers for the F5 and F2 genes and four allele-specific, dual-labeled hydrolysis probes essential for detecting the mutations.
  • FV-PTH mpx WT-Control: A control representing the wild type for both mutations is provided to ensure the accuracy of the assay.
  • FV-PTH mpx MUT-Control: This control represents the homozygous mutant genotypes for the FV and PTH mutations, serving as a reference point for the assay.

Explore Related Items